Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cancer Drug Targets
  4. Volume 25, Issue 1
  5. Article
Volume 25, Issue 1
  • ISSN: 1568-0096
  • E-ISSN: 1873-5576

Abstract

Background

Trastuzumab deruxtecan (T-DXd) has shown promising outcomes as a second or subsequent-line treatment for human epidermal growth factor-2 (HER2)-positive advanced gastric or gastroesophageal junction cancer.

Case Presentation

We reported a 49-year-old male patient with stage IV -amplified gastric cancer. Despite extensive pretreatments, including first-line trastuzumab plus FOLFOX, second-line trastuzumab plus FOLFOX, followed by traditional Chinese medicine, third-line nivolumab plus trastuzumab, fourth-line pyrotinib plus paclitaxel and five hepatic arterial chemoembolization procedures, and fifth-line pembrolizumab plus nab-paclitaxel and thoracic radiotherapy, the patient experienced disease progression. In April 2021, T-DXd was initiated as the sixth-line therapy in combination with radiotherapy for brain metastases. After one treatment cycle, the patient achieved a partial response. T-DXd was discontinued in August 2022 due to recurrent anemia attributed to cardiac stenosis-related bleeding.

Conclusion

The condition of the patient remained stable until May 2023, indicating a progression-free survival of over 24 months. This case suggests that T-DXd may offer long-term clinical benefits in patients with -amplified advanced gastric cancer with brain metastases.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096283210240209062301
2024-03-08
2024-11-21

  • From This Site

    /content/journals/ccdt/10.2174/0115680096283210240209062301
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ThriftA.P. WenkerT.N. El-SeragH.B. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention.Nat. Rev. Clin. Oncol.202320533834910.1038/s41571‑023‑00747‑036959359
     [Google Scholar]
  2. NCCN Clinical Practiuce Guidelines in Oncology (NCCN Guidelines) Gastric Cancer. Version 1.2023.Fort WashingtonNational Comprehensive Cancer Network2023
     [Google Scholar]
  3. LordickF. CarneiroF. CascinuS. FleitasT. HaustermansK. PiessenG. VogelA. SmythE.C. ESMO Guidelines Committee. Electronic address: [email protected] Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann. Oncol.202233101005102010.1016/j.annonc.2022.07.00435914639
     [Google Scholar]
  4. Japanese Gastric Cancer A. Japanese Gastric Cancer Treatment Guidelines 2021.Gastric Cancer.6th edition2023261125
     [Google Scholar]
  5. GreenblattK. KhaddourK. Trastuzumab.Treasure Island, FLStatPearls2023
     [Google Scholar]
  6. HayesD.F. PicardM.H. Heart of darkness: The downside of trastuzumab.J. Clin. Oncol.200624254056405810.1200/JCO.2006.07.514316908930
     [Google Scholar]
  7. MareiH.E. CenciarelliC. HasanA. Potential of antibody–drug conjugates (ADCs) for cancer therapy.Cancer Cell Int.202222125510.1186/s12935‑022‑02679‑835964048
     [Google Scholar]
  8. FuZ. LiS. HanS. ShiC. ZhangY. Antibody drug conjugate: The “biological missile” for targeted cancer therapy.Signal Transduct. Target. Ther.2022719310.1038/s41392‑022‑00947‑735318309
     [Google Scholar]
  9. ChauC.H. SteegP.S. FiggW.D. Antibody–drug conjugates for cancer.Lancet20193941020079380410.1016/S0140‑6736(19)31774‑X31478503
     [Google Scholar]
  10. OgitaniY. AidaT. HagiharaK. YamaguchiJ. IshiiC. HaradaN. SomaM. OkamotoH. OitateM. ArakawaS. HiraiT. AtsumiR. NakadaT. HayakawaI. AbeY. AgatsumaT. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1.Clin. Cancer Res.201622205097510810.1158/1078‑0432.CCR‑15‑282227026201
     [Google Scholar]
  11. OgitaniY. HagiharaK. OitateM. NaitoH. AgatsumaT. Bystander killing effect of DS -8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.Cancer Sci.201610771039104610.1111/cas.1296627166974
     [Google Scholar]
  12. ShitaraK. IwataH. TakahashiS. TamuraK. ParkH. ModiS. TsurutaniJ. KadowakiS. YamaguchiK. IwasaS. SaitoK. FujisakiY. SugiharaM. ShahidiJ. DoiT. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: A dose-expansion, phase 1 study.Lancet Oncol.201920682783610.1016/S1470‑2045(19)30088‑931047804
     [Google Scholar]
  13. ShitaraK. BangY.J. IwasaS. SugimotoN. RyuM.H. SakaiD. ChungH.C. KawakamiH. YabusakiH. LeeJ. SaitoK. KawaguchiY. KamioT. KojimaA. SugiharaM. YamaguchiK. DESTINY-Gastric01 Investigators Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.N. Engl. J. Med.2020382252419243010.1056/NEJMoa200441332469182
     [Google Scholar]
  14. YoshidaJ. SugiyamaK. SatohM. ShiraishiK. NishiboriR. KitagawaC. Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis.Curr. Probl. Cancer202145610075710.1016/j.currproblcancer.2021.10075733892964
     [Google Scholar]
  15. OgataT. FujitaY. MuroK. Dramatic response to trastuzumab deruxtecan rechallenge in a patient with HER2-positive gastric cancer: A case report.Am. J. Case Rep.202223e93560010.12659/AJCR.93560035241641
     [Google Scholar]
  16. KingD.A. WeielJ.J. ReyesR. MillsM. ItchonA. FisherG.A. FordJ.M. SuarezC.J. Therapeutic implications of oncogenic missense HER2 ( ERBB2 ) mutations in gastric adenocarcinoma.JCO Precis. Oncol.202377e220009310.1200/PO.22.0009336787506
     [Google Scholar]
  17. TerashimaT. YamashitaT. TakabatakeH. NakanumaS. KinoshitaJ. YagiS. MizukoshiE. HaradaK. FushidaS. KanekoS. Successful second conversion surgery after trastuzumab deruxtecan for recurrent HER2-positive gastric cancer.Clin. J. Gastroenterol.202316333033510.1007/s12328‑023‑01764‑336708503
     [Google Scholar]
  18. AmagaiH. SasagawaS. KoideY. TsukamotoS. MiyazawaY. YamakawaH. MurayamaH. SentsuiT. MatsubaraH. YamazakiK. YaritaT. A patient with afp-producing gastric cancer and stenosis who regained oral intake capabilities after T-DXd treatment].Cancer Sci.202350781381637496227
     [Google Scholar]
  19. TaniguchiH. YagisawaM. SatohT. KadowakiS. SunakawaY. NishinaT. KomatsuY. EsakiT. SakaiD. DoiA. KajiwaraT. OnoH. AsanoM. HiranoN. OdegaardJ.I. FujiiS. NomuraS. SatoA. YoshinoT. NakamuraY. Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).J. Clin. Oncol.20234116_supplSuppl.3014301410.1200/JCO.2023.41.16_suppl.3014
     [Google Scholar]
  20. ShitaraK. BangY. IwasaS. SugimotoN. RyuM. SakaiD. ChungH. OmuroY. KawakamiH. YabusakiH. SakamotoY. NishinaT. InakiK. KuwaharaY. SutoF. SugiharaM. SaitoK. KojimaA. YamaguchiK. O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma.Ann. Oncol.202132S22410.1016/j.annonc.2021.05.018
     [Google Scholar]
  21. ZhangL. HamdaniO. GjoerupO. Cho-PhanC. SniderJ. CastellanosE. NimeiriH. FramptonG. VenstromJ.M. OxnardG. KlempnerS.J. SchrockA.B. ERBB2 copy number as a quantitative biomarker for real-world outcomes to anti–human epidermal growth factor receptor 2 therapy in advanced gastroesophageal adenocarcinoma.JCO Precis. Oncol.202266e210033010.1200/PO.21.0033035050711
     [Google Scholar]
  22. GaoJ. WangH. ZangW. LiB. RaoG. LiL. YuY. LiZ. DongB. LuZ. JiangZ. ShenL. Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer.Cancer Sci.201710891881188710.1111/cas.1331428677165
     [Google Scholar]
  23. ZhangC. ChenZ. ChongX. ChenY. WangZ. YuR. SunT. ChenX. ShaoY. ZhangX. GaoJ. ShenL. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies.Clin. Transl. Med.2020108e25410.1002/ctm2.25433377634
     [Google Scholar]
  24. WangH. LiB. LiuZ. GongJ. ShaoL. RenJ. NiuY. BoS. LiZ. LaiY. LuS. GaoJ. ShenL. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.Eur. J. Cancer2018889210010.1016/j.ejca.2017.10.03229207318
     [Google Scholar]
  25. HinoK. NishinaT. KajiwaraT. BandoH. NakamuraM. KadowakiS. MinashiK. YukiS. OhtaT. HaraH. MizukamiT. MoriwakiT. OhtsuboK. KomodaM. MitaniS. NagashimaF. KatoK. YamadaT. HasegawaH. YamazakiK. YoshinoT. HyodoI. Association of ERBB2 copy number and gene coalterations with trastuzumab efficacy and resistance in human epidermal growth factor receptor 2–positive esophagogastric and gastric cancer.JCO Precis. Oncol.202266e220013510.1200/PO.22.0013535952320
     [Google Scholar]
  26. HanS. LimK.S. BlackburnB.J. YunJ. PutnamC.W. BullD.A. WonY.W. The potential of topoisomerase inhibitor-based antibody–drug conjugates.Pharmaceutics2022148170710.3390/pharmaceutics1408170736015333
     [Google Scholar]
  27. SasakiA. KawazoeA. EtoT. OkunakaM. MishimaS. SawadaK. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer.ESMO Open.20204Suppl 210.1136/esmoopen‑2020‑000775
     [Google Scholar]
  28. Kankeu FonkouaL.A. ChakrabartiS. SonbolM.B. KasiP.M. StarrJ.S. LiuA.J. NevalaW.K. MausR.L. BoisM.C. PitotH.C. ChandrasekharanC. RossH.J. WuT.T. GrahamR.P. VillasboasJ.C. WeissM. FosterN.R. MarkovicS.N. DongH. YoonH.H. Outcomes on anti-VEGFR -2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.Int. J. Cancer2021149237838610.1002/ijc.3355933739449
     [Google Scholar]
  29. TincknellG. NaveedA. NankervisJ. MukhtiarA. PiperA.K. BeckerT.M. ChantrillL. AghmeshehM. VineK.L. RansonM. BrungsD. HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis.Cancers20221423575410.3390/cancers1423575436497236
     [Google Scholar]
  30. StemmlerH.J. SchmittM. WillemsA. BernhardH. HarbeckN. HeinemannV. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier.Anticancer Drugs2007181232810.1097/01.cad.0000236313.50833.ee17159499
     [Google Scholar]
/content/journals/ccdt/10.2174/0115680096283210240209062301
Loading
Twenty-four-month Progression-free Survival in HER2-amplified Advanced Gastric Cancer with Brain Metastases after Trastuzumab Deruxtecan Treatment: A Case Report and Literature Review
Curr. Cancer Drug Targets< 25, 96 (2025); https://doi.org/10.2174/0115680096283210240209062301
/content/journals/ccdt/10.2174/0115680096283210240209062301
/content/journals/ccdt/10.2174/0115680096283210240209062301
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s web site along with the published article.

file format download Download

  • Article Type:     Case Report
Keyword(s): brain metastases; case report; ErbB-2; progression-free survival; receptor; Stomach neoplasms; trastuzumab deruxtecan

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test